The global clinical chemistry analyzers market size is projected to reach USD 16.5 billion by 2028 from USD 13.0 billion in 2023, at a CAGR of 4.9% during the forecast period. Continuous technological advancements have been the driving force behind the constant innovation in the clinical chemistry analyzers market. Ongoing research and development efforts, along with the incorporation of advanced software technologies in clinical laboratories, are set to shape the future of clinical chemistry analyzers. Moreover, stakeholders are expected to focus on developing new products that align with the evolving needs of laboratories. However, the market growth of clinical chemistry analyzers is anticipated to be somewhat restricted in the coming years due to challenges such as high capital investment requirements, a shortage of clinical laboratory technicians, and the availability of refurbished products.
The major players in clinical chemistry analyzers market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France),
To know about the assumptions considered for the study download the pdf brochure
In 2022, F. Hoffmann-La Roche Ltd. (Switzerland) emerged as the market leader in the clinical chemistry analyzers market, primarily due to its extensive product portfolio. The company's renowned brand, cobas, offers a diverse range of analyzers and reagents that are widely utilized by end users worldwide. Additionally, Roche Diagnostics boasts a broad global presence, encompassing North America, Europe, the Middle East, Africa, and Asia, enabling them to serve customers across different regions. To sustain its prominent position in the market, Roche Diagnostics primarily focuses on product launches and strategic partnerships and collaborations.
In 2022, Danaher Corporation (US) accounted for the second-largest share of the clinical chemistry analyzers market. The company operates across Europe, North America, and the Asia Pacific regions, boasting a global network of 242 manufacturing and distribution facilities. Through its subsidiary, Beckman Coulter Inc. (US), Danaher Corporation is actively engaged in the in vitro diagnostics market. The company's commitment to product development and launches plays a vital role in maintaining its market position. Additionally, strategic acquisitions serve as a growth strategy for expanding its product portfolio and market presence.
Abbott Laboratories (US) held the third-largest share in the clinical chemistry analyzers market. The company attained this prominent position primarily through its acquisition of Alere Inc. (US) in 2017. This strategic acquisition bolstered Abbott'ss diagnostics portfolio and positioned it as a key player in the point-of-care testing market. With a strong presence in the US, Abbott aims to expand its geographical reach by strengthening its business operations in emerging high-growth markets. The company's robust product portfolio has played a pivotal role in maintaining and augmenting its presence in the clinical chemistry analyzers market.
Clinical Chemistry Analyzers Market by Product (Fully-automated and PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) & Region - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE